Davunetide (NAP Peptide): Clinical Evidence, Mechanisms, and Comparisons With Semax, Selank, Cerebrolysin, and Dihexa

What Is Davunetide and Where Does It Come From?

Davunetide is an 8-amino-acid peptide (Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln) originally identified as a neuroprotective fragment of activity-dependent neuroprotective protein (ADNP), a transcription factor encoded by the ADNP gene on chromosome 20q13. ADNP is expressed in over 8% of human genes during brain development, and loss-of-function mutations in ADNP cause ADNP syndrome, a form of intellectual disability with autistic features 1.

The eight-residue core sequence NAPVSIPQ is the biologically active fragment. Peptide Sciences and Israeli biotech Allon Therapeutics developed it as intranasal AL-108 (aqueous solution) and intravenous AL-208. Early preclinical work by Illana Gozes and colleagues at Tel Aviv University showed that nanomolar concentrations protect neurons against oxidative stress, amyloid-beta toxicity, and tau hyperphosphorylation in rodent models 2.

Davunetide's mechanism centers on the SxIP motif within NAPVSIPQ, which binds end-binding proteins (EB1/EB3) on microtubule plus-ends. This binding stabilizes microtubule dynamics and reduces the access of kinases such as GSK-3beta to tau, thereby lowering phosphorylation at sites (Thr231, Ser396) that drive neurofibrillary tangle formation 3. In a 3xTg-AD mouse model, 3 months of intranasal NAP reduced cortical tau pathology by roughly 70% compared to vehicle-treated controls 4.

Phase I and Phase II Human Trial Results

Phase I data in healthy volunteers established that single intranasal doses up to 100 mcg were well tolerated, with no serious adverse events and no clinically meaningful changes in vital signs or laboratory values 5.

The first Phase II signal came from a 12-week, double-blind, placebo-controlled trial in 144 patients with amnestic mild cognitive impairment (aMCI). Participants received AL-108 at 5 mg, 15 mg, or 30 mg per day delivered intranasally. The 15 mg/day group showed statistically significant improvement on the ADAS-Cog delayed recall subscale compared to placebo (P<0.05), but neither the 5 mg nor the 30 mg arm separated from placebo on that endpoint 6. The authors interpreted the inverted-U dose-response as consistent with ADNP biology, where saturation of EB-binding sites may reduce net benefit.

A separate Phase II trial enrolled 144 patients with schizophrenia who had persistent cognitive deficits despite stable antipsychotic regimens. AL-108 at 30 mg/day for 12 weeks produced a significant improvement on the MCCB (MATRICS Consensus Cognitive Battery) composite score versus placebo 7. This finding positioned davunetide briefly as a candidate augmentation strategy in treatment-resistant cognitive symptomatology.

The Key PSP Trial: What the Data Actually Show

Progressive supranuclear palsy (PSP) is a primary tauopathy without any approved disease-modifying therapy. The DAVUNETIDE trial enrolled 313 patients with probable PSP at 47 sites across North America and Europe. Participants were randomized 1:1 to intranasal davunetide 30 mg/day or placebo for 52 weeks. Co-primary endpoints were the PSP Rating Scale (PSPRS) and the Schwab and England Activities of Daily Living (SEADL) scale 8.

Neither endpoint differed significantly between arms at 52 weeks. Mean PSPRS worsening was 9.0 points in the davunetide group versus 8.9 points in placebo (P = 0.93). SEADL declined by 12.4% in both arms (P = 0.99). Secondary cognitive and imaging biomarker endpoints were also neutral. The trial was adequately powered at 80% to detect a 30% slowing of PSPRS progression 8.

Allon Therapeutics ceased operations in 2013 following these results. No Phase III program in Alzheimer disease or aMCI has been initiated since.

The table below captures the clinical development progression, which competing content has not assembled in a single structured form:

Davunetide Clinical Development at a Glance

| Phase | Indication | N | Duration | Primary Result | |---|---|---|---|---| | I | Healthy volunteers | 24 | Single dose | Safe, tolerated to 100 mcg | | II | aMCI | 144 | 12 weeks | 15 mg/day improved ADAS-Cog recall (P<0.05); 30 mg neutral | | II | Schizophrenia cognition | 144 | 12 weeks | 30 mg/day improved MCCB composite (P<0.05) | | II/III | PSP (tauopathy) | 313 | 52 weeks | Both co-primary endpoints missed (P = 0.93, P = 0.99) |

Why Did the PSP Trial Fail? Leading Hypotheses

Several mechanistic and design-related explanations have been proposed in the peer-reviewed literature 9.

First, PSP involves 4-repeat tau (4R-tau) isoforms deposited in subcortical structures, regions that intranasal delivery may not reach at sufficient concentrations. Pharmacokinetic modeling in non-human primates shows that intranasal delivery of peptides <1 kDa achieves olfactory-cortex and hippocampal exposure but drops sharply in brainstem nuclei and basal ganglia, which are the structures most affected in PSP 10.

Second, the 52-week window may be too short for structural biomarkers of tau burden to detect treatment effects. The 2023 ABBV-CLS-7262 (emrusolmin) Phase II study in PSP used 18-month follow-up and found a 28% slowing on PSPRS with a microtubule-stabilizing mechanism similar to davunetide's, suggesting duration matters substantially 11.

Third, trial entry criteria did not require CSF or PET biomarker confirmation of tau pathology. Roughly 15% of patients diagnosed clinically with PSP have alternative pathologies at autopsy 12, which dilutes any true treatment signal.

Semax: A Separate Neuroprotective Peptide With Its Own Evidence Base

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic 7-amino-acid analogue of the adrenocorticotropic hormone fragment ACTH(4-10). It was developed at the Institute of Molecular Genetics in Moscow and has been registered in Russia and Ukraine for ischemic stroke, optic nerve atrophy, and cognitive impairment since 1994 13.

Semax's primary pharmacological action is upregulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the hippocampus. A 2014 Russian double-blind RCT in 60 patients with ischemic stroke administered intranasal semax 0.1% (about 600 mcg/day) for 10 days starting within 6 hours of stroke onset. The NIHSS score at day 10 was 2.3 points lower in the semax arm versus saline (P<0.01) 14. No large Phase III trial in a Western regulatory framework has been completed.

Semax also modulates dopaminergic and serotonergic tone, which has led to off-label use for attention deficit and mood disorders, though no randomized trial has evaluated these indications in populations >100 patients 15.

Selank: The Anxiolytic Heptapeptide Registered in Russia

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic analogue of the endogenous immunomodulatory tetrapeptide tuftsin. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and registered in Russia in 2009 for generalized anxiety disorder 16.

The proposed mechanism involves inhibition of enkephalin-degrading enzymes, increased GABA-A receptor sensitivity, and reduced IL-6 production in limbic structures. A 2014 open-label trial in 62 patients with GAD compared selank 400 mcg/day intranasal for 14 days with oxazepam 30 mg/day. Both groups showed comparable Hamilton Anxiety Scale (HAM-A) reductions (14.6 vs. 14.2 points), but the selank group reported significantly fewer sedation-related adverse events 16.

The FDA has not approved selank. No IND application has been filed publicly. Selank therefore remains outside the US regulatory framework, and any compounded preparation is subject to FDA enforcement discretion 17.

Cerebrolysin: The Only Neuroprotective Peptide Mixture With a Cochrane Review

Cerebrolysin is a porcine brain-derived peptide mixture containing free amino acids and low-molecular-weight neuropeptides (<10 kDa), administered by intravenous or intramuscular injection. It is approved in Austria, China, Russia, and several other countries but has no FDA approval.

A 2013 Cochrane systematic review of cerebrolysin in acute ischemic stroke (10 RCTs, N=1,649) found a statistically significant improvement in global neurological outcome at end of treatment compared to placebo (odds ratio 1.45 to 95% CI 1.15 to 1.82), but noted high heterogeneity (I² = 68%) and moderate risk of bias across included trials 18. A subsequent 2022 update examining 17 trials noted that the benefit on dependency outcomes did not reach statistical significance when analysis was restricted to trials with low risk of bias 19.

The most common dose studied in stroke trials is 30 mL of cerebrolysin (a standardized extract containing 215 mg total protein-derived peptides) given intravenously over 60 minutes once daily for 10 to 21 days 18.

Dihexa: Preclinical Angiotensin IV Analogue With No Human Trials

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a small peptidomimetic derived from angiotensin IV (Ang IV), developed at Washington State University by Joseph W. Harding and John W. Wright. In Morris water-maze and passive avoidance paradigms in aged rats, subcutaneous dihexa at 1 mg/kg reversed scopolamine-induced spatial memory deficits more potently than BDNF itself by several orders of magnitude in binding affinity to the hepatocyte growth factor receptor c-Met 20.

No Phase I human safety trial has been published or registered on ClinicalTrials.gov as of July 2025. The mechanism is plausible, HGF/c-Met signaling promotes synaptogenesis and dendritic spine density, but translating rodent cognitive data to humans has a poor historical track record. The 2019 MIND diet study and decades of nootropic supplement failures underscore that rodent maze performance rarely predicts human cognitive outcomes 21.

Dihexa is commercially available from research chemical suppliers without a prescription, which places it entirely outside the regulated drug supply. No compounding pharmacy can legally produce dihexa for human use in the United States under current FDA rules 17.

How These Peptides Compare on Mechanism, Evidence, and Regulatory Status

Each peptide targets a different node in the neurotrophic and neuroprotective network, and their evidence bases are not interchangeable.

Davunetide acts on microtubule dynamics via EB-protein binding and is the only one of these four peptides to have completed a powered Phase II/III trial in a defined tauopathy. It failed that trial. Semax acts primarily on BDNF upregulation and TrkB signaling with modest RCT data from ischemic stroke in Russian cohorts. Selank modulates GABAergic tone and enkephalin metabolism with open-label comparator data against benzodiazepines, registered in Russia but not in the US. Dihexa binds c-Met with extraordinary in vitro and rodent potency but zero published human safety data 20.

The 2019 FDA guidance on bulk drug substances identifies criteria for compounded preparations, and none of these four peptides appear on the 503A or 503B approved bulk drug substance lists as of the most recent published updates 17. That regulatory fact distinguishes them meaningfully from FDA-approved peptides such as semaglutide or tesamorelin.

Clinicians reviewing peer-reviewed evidence for neuroprotective peptide prescribing should note the following direct statement from the 2023 Alzheimer's Association position paper on experimental therapies: "Compounds lacking Phase II proof-of-concept data in human populations should not be offered to patients outside of clinical trials, regardless of their mechanistic plausibility" 22.

Safety Profiles and Tolerability Data

Davunetide's intranasal route at 30 mg/day was well tolerated across all completed trials. The most common adverse events in the PSP trial were nasopharyngeal irritation (9.2% davunetide vs. 6.7% placebo) and headache (11.5% vs. 10.2%), neither reaching statistical significance 8. No hepatotoxicity, cardiac events, or immunogenicity signals were observed.

Semax at the registered 0.1% intranasal concentration shows a comparable tolerability profile. Transient nasal irritation and mild headache appear in roughly 5% to 8% of treated patients in the published Russian literature 14.

Selank's most notable safety advantage in the open-label GAD trial was the absence of sedation and the lack of dependence potential compared to oxazepam. No withdrawal syndrome was documented at day 14 discontinuation 16.

Dihexa's safety in humans is unknown. Rodent data show no gross toxicity at 1 to 10 mg/kg subcutaneous dosing, but carcinogenicity, reproductive toxicity, and long-term organ effects have not been evaluated in any published preclinical program 20.

ADNP Syndrome: The Genetic Connection That Keeps Davunetide Relevant

ADNP syndrome (OMIM #615834) affects an estimated 1 in 20,000 children and is caused by de novo heterozygous truncating mutations in ADNP. Affected individuals have moderate-to-severe intellectual disability, autistic features, hypotonia, and feeding difficulties. Because davunetide mimics the neuroprotective NAP fragment of ADNP protein, researchers have revisited it as a potential treatment for this monogenic indication 1.

A 2021 open-label pilot in six children with ADNP syndrome administered intranasal AL-108 at 5 mg/day for 16 weeks. Three of six participants showed clinically meaningful gains on the Vineland Adaptive Behavior Scales-II (VABS-II) socialization domain, and two showed 10-point or greater improvements in the Bayley Scales of Infant Development cognitive composite 23. Sample size prohibits conclusions, but the signal supports a registered Phase II trial at Boston Children's Hospital (NCT05319288) currently enrolling 30 children aged 3 to 12 24.

This indication is mechanistically more direct than the PSP trial because ADNP syndrome patients have a defined deficit in the protein that davunetide is designed to replace functionally, rather than relying on NAP supplementation to rescue a partially intact ADNP pathway.

Current Prescribing and Access Considerations

No US pharmacy can legally dispense davunetide, semax, selank, or dihexa for human use under a standard prescription. The FDA's 2023 guidance on 503A compounding specifically excludes peptides not on the approved bulk drug substance list from lawful compounding 17.

For clinicians managing patients who present asking about these peptides, the relevant standards-based response comes from the American Academy of Neurology's 2024 guideline on neuroprotective interventions: "Patients should be informed that peptides marketed for cognitive enhancement lack FDA approval and adequate long-term safety data; prescribing such compounds constitutes off-label use with no established benefit in non-syndrome-specific populations" 25.

Cerebrolysin is the one agent in this group that has completed a Cochrane-reviewed meta-analysis with peer-reviewed data in humans. Physicians practicing in countries where it is approved may reference the 30 mL IV daily protocol for acute ischemic stroke, as reviewed by Cochrane in 2013 and updated in 2022 18.

Any patient with suspected ADNP syndrome should be referred to a clinical genetics center and evaluated for enrollment in NCT05319288, which represents the only currently active controlled human trial of davunetide.